临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 29110-48-3

Guanfacine Hydrochloride

中文名称:盐酸胍法辛
CAS号:29110-48-3
分子式: C9H9Cl2N3O.HCl 分子量: 282.55
产品形式: hydrochloride
研发状态: Completed
研发用途: Attention Deficit Hyperactivity Disorder (ADHD)
研究机构: Shire; Takeda
研发日期: March 11 2019
研发阶段: --
Guanfacine Hydrochloride (Tenex, Intuniv) is a selective α2A-adrenoceptor agonist with anti-hypertensive effect.

CAS: 29094-61-9

Glipizide

中文名称:格列吡嗪
CAS号:29094-61-9
分子式: C21H27N5O4S 分子量: 445.54
产品形式: free base
研发状态: Recruiting
研发用途: Pancreatic Cancer; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
研究机构: Memorial Sloan Kettering Cancer Center
研发日期: December 5 2023
研发阶段: Phase 2
Glipizide (CP-28720,K 4024) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.

CAS: 29031-19-4

Glucosamine sulfate

中文名称:D-氨基葡萄糖硫酸钾盐
CAS号:29031-19-4
分子式: C6H13NO5.H2SO4 分子量: 277.25
产品形式: sulfate
研发状态: Completed
研发用途: Healthy Subject; Overweight
研究机构: Fred Hutchinson Cancer Center
研发日期: August 1 2017
研发阶段: Phase 1
Glucosamine sulfate (D-Glucosaminesulfate, D-Glucosamine sulphate) is a dietary supplement commonly used in the treatment of osteoarthritis. It is a type of glycosaminoglycan, which is a naturally occurring major component of joint cartilage and joint fluid.

CAS: 290297-26-6

Netupitant

中文名称:奈妥匹坦
CAS号:290297-26-6
分子式: C30H32F6N4O 分子量: 578.59
产品形式: Free Base
研发状态: Completed
研发用途: Healthy
研究机构: HK inno.N Corporation
研发日期: March 18 2021
研发阶段: Phase 1
Netupitant (CID6451149) is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity.

CAS: 289-95-2

Pyrimidine

中文名称:嘧啶
CAS号:289-95-2
分子式: C4H4N2 分子量: 80.09
产品形式: free base
研发状态: Recruiting
研发用途: Melanoma (Skin)
研究机构: Centre Hospitalier Universitaire de Nice
研发日期: May 25 2022
研发阶段: Not Applicable
Pyrimidines are heterocyclic, six-membered, nitrogen-containing carbon ring structures, with uracil, cytosine and thymine being the basal structures of ribose-containing nucleosides (uridine, cytidine, and thymidine respectively), or deoxyribose-containing deoxynucleosides, and their corresponding ribonucleotides or deoxyribonucleotides. Pyrimidines serve essential functions in human metabolism as ribonucleotide bases in RNA (uracil and cytosine), and as deoxyribonucleotide bases in DNA (cytosine and thymine), and are linked by phosphodiester bridges to purine nucleotides in double-stranded DNA, in both the nucleus and the mitochondria. Pyrimidine activated sugars are also involved in polysaccharide and phospholipid synthesis, glucuronidation in detoxification processes, glycosylation of proteins and lipids and in the recently identified novel endothelium-derived vasoactive dinucleotides.

CAS: 289499-45-2

Canertinib dihydrochloride

中文名称:卡纽替尼二盐酸盐
CAS号:289499-45-2
分子式: C24H27Cl3FN5O3 分子量: 558.86
产品形式: Dihydrochloride
研发状态: Completed
研发用途: Lung Neoplasms
研究机构: Pfizer
研发日期: Jan-03
研发阶段: Phase 2
Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively.